Gamida Cell-Teva JV gets DMC nod to continue enrolment of patients for phase-III trial of StemEx
Saturday, February 13, 2010 11:00 IST Jerusalem, Israel
The Gamida Cell-Teva Joint Venture (JV) announced that the Data Monitoring Committee (DMC) has independently reviewed preliminary data from the pivotal registration, phase-III